Inflammatory lipid biomarkers and transplant-free mortality risk in hepatitis B-related cirrhosis and hepatic encephalopathy

被引:0
|
作者
Shi, Ke [1 ]
Wang, Xiaojing [1 ]
Yi, Zhang [1 ]
Li, Yanqiu [1 ]
Feng, Ying [1 ]
Wang, Xianbo [1 ]
机构
[1] Capital Med Univ, Beijing Ditan Hosp, Ctr Integrat Med, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatitis B virus; hepatic encephalopathy; model end-stage liver disease score; inflammatory; high density lipoprotein cholesterol; PATHOPHYSIOLOGY; PREDICTORS; METABOLISM;
D O I
10.3389/fmed.2025.1528733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Inflammatory reactions and dyslipidemia are associated with the pathogenesis and prognosis of hepatitis B virus-related cirrhosis. We aimed to assess the predictive ability of these parameters in patients with hepatitis B virus-related cirrhosis and overt hepatic encephalopathy (HBV-related OHE). Design We conducted an analysis of 1,404 participants diagnosed with HBV-related OHE between January 2008 and July 2023. The prognostic significance of the neutrophil-to-high-density lipoprotein cholesterol (HDL-C) ratio (NHR), lymphocyte-to-HDL-C ratio (LHR), and monocyte-to-HDL-C ratio (MHR) was evaluated using the area under the receiver operating characteristic curve (AUC). Restrictive cubic splines (RCS) were employed to explore the relationship between NHR and 12-month transplant-free (TF) mortality. This study included a prospective test cohort of 328 patients. Results NHR was identified as an independent risk factor for 12-month TF mortality. The AUC for NHR (0.776) was similar to that of the model end-stage liver disease (MELD) score (AUC: 0.777). In the test cohort, NHR demonstrated AUC values comparable to MELD, with significantly higher AUCs than LHR and MHR (both p < 0.05). Based on cutoff values for NHR and MELD, patients were classified into four risk subgroups: very-low (NHR < 10 and MELD <18), low (NHR >= 10 and MELD <18), moderate (NHR < 10 and MELD >= 18), and high (NHR >= 10 and MELD >= 18). The 12-month TF mortality rates in the training cohort were 7.2, 23.5, 30.8, and 51.4%, respectively, for these subgroups, while in the test cohort, the rates were 8.7, 20.5, 30.7, and 46.0%. Conclusion NHR is a valuable and accessible prognostic indicator for 12-month TF mortality in patients with HBV-related OHE. Patients with both NHR >= 10 and MELD >= 18 are at the highest risk of mortality.
引用
收藏
页数:12
相关论文
共 48 条
  • [31] Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment
    Huang, Xixia
    Wang, Hong
    Zhang, Wenhong
    Gu, Erli
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (05) : 546 - 552
  • [32] High-density lipoprotein cholesterol as a prognostic marker for 90-day transplant-free mortality in hepatitis B virus-related acute-on-chronic liver failure
    Shi, Ke
    Zhang, Yi
    Li, Yanqiu
    Wang, Xiaojing
    Feng, Ying
    Wang, Xianbo
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2025, 14
  • [33] Inflammatory pseudotumor mimicking primary hepatic malignant tumor with hepatitis B virus-related cirrhosis: A case report
    Ke, Qinghong
    Fan, Le
    Duan, Xin
    He, Zenglei
    Zheng, Shusen
    ONCOLOGY LETTERS, 2013, 6 (02) : 550 - 552
  • [34] The Combination of Shear Wave Elastography and Platelet Counts Can Effectively Predict High-Risk Varices in Patients with Hepatitis B-Related Cirrhosis
    Xie, Xiaoyu
    Feng, Yuemin
    Lyu, Zhuozhen
    Wang, Le
    Yang, Yao
    Bai, Yuping
    Liu, Chenxi
    Wu, Hao
    Ren, Wanhua
    Zhu, Qiang
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [35] Abnormal Regional Homogeneity and Functional Connectivity of Baseline Brain Activity in Hepatitis B Virus-Related Cirrhosis With and Without Minimal Hepatic Encephalopathy
    Sun, Qing
    Fan, Wenliang
    Ye, Jin
    Han, Ping
    FRONTIERS IN HUMAN NEUROSCIENCE, 2018, 12
  • [36] Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study
    Hou, Yixin
    Yan, Jianguo
    Shi, Ke
    Liu, Xiaoli
    Gao, Fangyuan
    Wu, Tong
    Meng, Peipei
    Zhang, Min
    Jiang, Yuyong
    Wang, Xianbo
    ONCOTARGETS AND THERAPY, 2024, 17 : 215 - 226
  • [37] Lobe-Based Hepatic Uptake Index of Gd-EOB-DTPA on Contrast-Enhanced MRI to Quantitatively Discriminate between Compensated and Decompensated Hepatitis B-Related Cirrhosis
    Lu, Fulin
    Tan, Bangguo
    Huang, Yucheng
    Xu, Lin
    Wu, Changqiang
    Zhou, Haiying
    Li, Rui
    Zhang, Xiaoming
    Chen, Tianwu
    Li, Hongjun
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 2024
  • [38] Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis
    Nagaoki, Yuko
    Aikata, Hiroshi
    Daijyo, Kana
    Teraoka, Yuji
    Honda, Fumi
    Nakamura, Yuki
    Hatooka, Masahiro
    Morio, Kei
    Fujino, Hatsue
    Nakahara, Takashi
    Kawaoka, Tomokazu
    Miki, Daiki
    Tsuge, Masataka
    Hiramatsu, Akira
    Imamura, Michio
    Kawakami, Yoshiiku
    Ochi, Hidenori
    Chayama, Kazuaki
    HEPATOLOGY RESEARCH, 2018, 48 (04) : 264 - 274
  • [39] Prognostic value of decline in model for end-stage liver disease score and hepatic encephalopathy in hepatitis B-related acute-on-chronic liver failure patients treated with plasma exchange
    Wang, Lu
    Zhu, Shu
    Liu, Ying
    Zheng, Lihua
    Xu, Wenxiong
    Luo, Qiumin
    Zhang, Yeqiong
    Deng, Hong
    Li, Xinhua
    Xie, Chan
    Peng, Liang
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (09) : 1089 - 1096
  • [40] Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naive patients with chronic hepatitis B-related compensated cirrhosis in Taiwan
    Hu, Tsung-Hui
    Chiu, Sherry Yueh-Hsia
    Tseng, Po-Lin
    Chen, Chien-Hung
    Lu, Sheng-Nan
    Wang, Jing-Houng
    Hung, Chao-Hung
    Kee, Kwong-Ming
    Lin, Ming-Tsung
    Chang, Kuo-Chin
    Lin, Meng-Chih
    Chien, Rong-Nan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (11-12) : 1695 - 1706